• Something wrong with this record ?

Epidemiology, genetics and treatment of multiple myeloma and precursor diseases

K. Hemminki, A. Försti, R. Houlston, A. Sud

. 2021 ; 149 (12) : 1980-1996. [pub] 20210830

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't, Review

Persistent link   https://www.medvik.cz/link/bmc22003022

Grant support
C1298/A8362 Cancer Research UK (C1298/A8362)

Multiple myeloma (MM) is a hematological malignancy caused by the clonal expansion of plasma cells. The incidence of MM worldwide is increasing with greater than 140 000 people being diagnosed with MM per year. Whereas 5-year survival after a diagnosis of MM has improved from 28% in 1975 to 56% in 2012, the disease remains essentially incurable. In this review, we summarize our current understanding of MM including its epidemiology, genetics and biology. We will also provide an overview of MM management that has led to improvements in survival, including recent changes to diagnosis and therapies. Areas of unmet need include the management of patients with high-risk MM, those with reduced performance status and those refractory to standard therapies. Ongoing research into the biology and early detection of MM as well as the development of novel therapies, such as immunotherapies, has the potential to influence MM practice in the future.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22003022
003      
CZ-PrNML
005      
20220127150732.0
007      
ta
008      
220113s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ijc.33762 $2 doi
035    __
$a (PubMed)34398972
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hemminki, Kari $u Biomedical Center, Faculty of Medicine, Charles University in Pilsen, Pilsen, Czech Republic $u Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
245    10
$a Epidemiology, genetics and treatment of multiple myeloma and precursor diseases / $c K. Hemminki, A. Försti, R. Houlston, A. Sud
520    9_
$a Multiple myeloma (MM) is a hematological malignancy caused by the clonal expansion of plasma cells. The incidence of MM worldwide is increasing with greater than 140 000 people being diagnosed with MM per year. Whereas 5-year survival after a diagnosis of MM has improved from 28% in 1975 to 56% in 2012, the disease remains essentially incurable. In this review, we summarize our current understanding of MM including its epidemiology, genetics and biology. We will also provide an overview of MM management that has led to improvements in survival, including recent changes to diagnosis and therapies. Areas of unmet need include the management of patients with high-risk MM, those with reduced performance status and those refractory to standard therapies. Ongoing research into the biology and early detection of MM as well as the development of novel therapies, such as immunotherapies, has the potential to influence MM practice in the future.
650    _2
$a nádorové biomarkery $x genetika $7 D014408
650    _2
$a cyklin D1 $x genetika $7 D019938
650    _2
$a exozom $x genetika $7 D063326
650    _2
$a genetická predispozice k nemoci $7 D020022
650    _2
$a histondemethylasy $x genetika $7 D056466
650    _2
$a lidé $7 D006801
650    _2
$a imunoterapie $x metody $7 D007167
650    _2
$a mnohočetný myelom $x diagnóza $x epidemiologie $x genetika $x terapie $7 D009101
650    _2
$a mutace $7 D009154
650    _2
$a plazmatické buňky $x imunologie $x patologie $7 D010950
650    _2
$a represorové proteiny $x genetika $7 D012097
650    _2
$a rizikové faktory $7 D012307
650    _2
$a míra přežití $7 D015996
650    _2
$a transkripční elongační faktory $x genetika $7 D035602
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Försti, Asta $u Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany $u Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany
700    1_
$a Houlston, Richard $u Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK
700    1_
$a Sud, Amit $u Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK $u The Department of Haemato-Oncology, The Royal Marsden Hospital NHS Foundation Trust, London, UK
773    0_
$w MED00002298 $t International journal of cancer $x 1097-0215 $g Roč. 149, č. 12 (2021), s. 1980-1996
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34398972 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127150728 $b ABA008
999    __
$a ok $b bmc $g 1750711 $s 1154171
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 149 $c 12 $d 1980-1996 $e 20210830 $i 1097-0215 $m International journal of cancer $n Int J Cancer $x MED00002298
GRA    __
$a C1298/A8362 $p Cancer Research UK (C1298/A8362)
LZP    __
$a Pubmed-20220113

Find record

Citation metrics

Archiving options